Depression Epidemiology Study

Global Depression Epidemiology Study

Depression Study Objective:

To determine the prevalence and incidence of Depression among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Depression within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Depression Study USP:

• This epidemiological study on Depression stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Depression related health problems.

• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Depression but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Depression cases.

Depression related Study Overview:

The study Defines Depression as an advanced form of disease. The significance of studying Depression epidemiology is due to its increasing prevalence in different age populations.

Depression Study Design:

Population: The target population and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Depression cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Cystic Fibrosis Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Depression and potential risk factors (e.g., age, smoking, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Depression study summary:

Depression study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Depression worldwide.

Depression Disease overview:

Depression is common and serious mental health disorder which is characterised by constant feeling of sadness, loss of interest or pleasure in any activities and wide range of emotional and physical symptoms interfering in patients’ daily life activities.

Major depressive disorder, persistent depressive disorder, bipolar disorder, seasonal affective disorder, postpartum depression, psychotic depression, premenstrual dysphoric disorder, atypical depression are some of the different types of Depression with which most the people in world suffer.

According to World Health Organisation (WHO), it is estimated that, 5% of adults globally, suffer from depression. And according to national institute of mental health (NIMH) in US about 21 million adults experience at least one major episode of depression in the year 2021D representing 8.3% of US adult population.

Various treatment options are available for treating depression which include, Pharmacological Treatment like prescription of antidepressants, Psychotherapy, Combined Treatment. Key market players in manufacturing the therapeutics for the treatment of depression are as follows; Roche, Pfizer, GSK, Bristol Myers Squibb, Teva Pharmaceutical Industries, Novartis, AbbVie, Takeda Pharmaceutical, AstraZeneca, Eli Lilly, Allergan plc, Sanofi, Johnson, Lundbeck.

January 2025, Johnson & Johnson announced that the U.S. FDA has approved SPRAVATO® (esketamine) nasal spray as the first and only monotherapy for adults with treatment-resistant depression (TRD). This approval follows a Priority Review and is based on data showing that SPRAVATO® alone led to rapid and superior improvement in depressive symptoms compared to placebo, with significant improvements seen as early as 24 hours and sustained through 28 days. This new monotherapy option aims to provide relief for patients who have not responded to at least two oral antidepressants.

Depression Demographic and Environmental Risk Factors:

Age and Sex: According to National Institute of Mental Health, it is reported that the prevalence rates in females were highest with 10.3% as compared to males with 6.2%, and it is seen to highest for 18 to 25 age group with 18.6%. 5 million adolescents aged 12 to 17 in US had at least one depressive episode, representing 20.1 %of 12 to 17 age US population and highest in adolescent females with 29.2% then 11. % males. Globally 10% of women in pregnancy and women who just delivered baby experience depression. Suicide due to depression is 4^th leading cause of death globally and observed in 15 to 29 years old age group.

Ethnicity: According to data from National Health and Nutrition Examination Survey, in US, prevalence of depression was found to be lowest in non-Hispanic Asian adults with 3.1 %, compared to Hispanics with 8.2%, non-Hispanic blacks with 9.2% adults and non-Hispanic white adults with 7.9%. another study reported prevalence rates in Hispanics to be 10.8% and 8.9% in African Americans and 7.8% in whites.

Risk Factors causing Depression: major factors which can be the reason for causing depression in different individuals are as follows, history of childhood trauma, psychological factors like low self-esteem, lack of social support, emotional, physical, sexual abuse, negative thinking patterns, poor nutrition, unresolved grief or loss, certain personality traits, many of the time therapeutics or medicines patient is taking for some other treatment can cause depression, substance abuse, family history and genetics, hormonal changes, chronic illness like cancer, diabetes, chronic pain also can be one of the reasons.

Depression Market Scope:

Drivers: increasing prevalence of mental disorders across the globe- is among the significant factors fueling the growth of the depression market. According to the World Health Organization (WHO), there has been a 13% increase in mental health conditions and other depressive disorders in the last decade. Similarly, according to the US Department of Health and Human Services (HHS), in 2020, it is estimated that 4.1 billion adolescents ages 12 and 17 had a major depressive episode, and 2.9 billion had a major depressive episode with severe impairment.

Therefore, the rising number of patients with related disorders is contributing to the growth in the global market. Additionally, several factors such as demographic changes, environmental conditions, and increasing mental stress are also resulting in rising mental health disorders, thereby fueling the market growth during the forecast period.

Restraints: Limited access to mental healthcare in developing countries, high treatment cause, side effects of antidepressants, stigma surrounding mental health- deterring individuals from seeking treatment for the suffering mental health issue, lack of awareness about the depression are some of the factors which contribute to hamper the growth of the Treatment market of Depression.